TY - JOUR
T1 - Characteristics and outcome of Pediatric Renal Cell Carcinoma patients registered in the International Society of Pediatric Oncology (SIOP) 93-01, 2001, and UK-IMPORT database
T2 - A report of the SIOP-Renal Tumor Study Group
AU - van der Beek, Justine N
AU - Hol, Janna A
AU - Coulomb-l'Hermine, Aurore
AU - Graf, Norbert
AU - van Tinteren, Harm
AU - Pritchard-Jones, Kathy
AU - Houwing, Maite E
AU - de Krijger, Ronald R
AU - Vujanic, Gordan M
AU - Dzhuma, Kristina
AU - Schenk, Jens-Peter
AU - Littooij, Annemieke S
AU - Ramírez-Villar, Gema L
AU - Murphy, Dermot
AU - Ray, Satyajit
AU - Al-Saadi, Reem
AU - Gessler, Manfred
AU - Godzinski, Jan
AU - Ruebe, Christian
AU - Collini, Paola
AU - Verschuur, Arnaud C
AU - Frisk, Tony
AU - Vokuhl, Christian
AU - Hulsbergen-van de Kaa, Christina A
AU - de Camargo, Beatriz
AU - Sandstedt, Bengt
AU - Selle, Barbara
AU - Tytgat, Godelieve A M
AU - van den Heuvel-Eibrink, Marry M
N1 - Funding Information:
We are indebted to the national coordinating centers that provided us with missing data. We would like to acknowledge Prof Dr med I. Leuschner (now deceased) and Dr J. de Kraker (now deceased) for their leadership in the SIOP-RTSG and consequent contribution. There was no role for the Stichting Kinderen Kankervrij funding in the study design, in the collection, analysis, interpretation of data, in the writing of the report and in the decision to submit the paper for publication.
Publisher Copyright:
© 2021 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
PY - 2021/6/1
Y1 - 2021/6/1
N2 - In children, renal cell carcinoma (RCC) is rare. This study is the first report of pediatric patients with RCC registered by the International Society of Pediatric Oncology-Renal Tumor Study Group (SIOP-RTSG). Pediatric patients with histologically confirmed RCC, registered in SIOP 93-01, 2001 and UK-IMPORT databases, were included. Event-free survival (EFS) and overall survival (OS) were analyzed using the Kaplan-Meier method. Between 1993 and 2019, 122 pediatric patients with RCC were registered. Available detailed data (n = 111) revealed 56 localized, 30 regionally advanced, 25 metastatic and no bilateral cases. Histological classification according to World Health Organization 2004, including immunohistochemical and molecular testing for transcription factor E3 (TFE3) and/or EB (TFEB) translocation, was available for 65/122 patients. In this group, the most common histological subtypes were translocation type RCC (MiT-RCC) (36/64, 56.3%), papillary type (19/64, 29.7%) and clear cell type (4/64, 6.3%). One histological subtype was not reported. In the remaining 57 patients, translocation testing could not be performed, or TFE-cytogenetics and/or immunohistochemistry results were missing. In this group, the most common RCC histological subtypes were papillary type (21/47, 44.7%) and clear cell type (11/47, 23.4%). Ten histological subtypes were not reported. Estimated 5-year (5y) EFS and 5y OS of the total group was 70.5% (95% CI = 61.7%-80.6%) and 84.5% (95% CI = 77.5%-92.2%), respectively. Estimated 5y OS for localized, regionally advanced, and metastatic disease was 96.8%, 92.3%, and 45.6%, respectively. In conclusion, the registered pediatric patients with RCC showed a reasonable outcome. Survival was substantially lower for patients with metastatic disease. This descriptive study stresses the importance of full, prospective registration including TFE-testing.
AB - In children, renal cell carcinoma (RCC) is rare. This study is the first report of pediatric patients with RCC registered by the International Society of Pediatric Oncology-Renal Tumor Study Group (SIOP-RTSG). Pediatric patients with histologically confirmed RCC, registered in SIOP 93-01, 2001 and UK-IMPORT databases, were included. Event-free survival (EFS) and overall survival (OS) were analyzed using the Kaplan-Meier method. Between 1993 and 2019, 122 pediatric patients with RCC were registered. Available detailed data (n = 111) revealed 56 localized, 30 regionally advanced, 25 metastatic and no bilateral cases. Histological classification according to World Health Organization 2004, including immunohistochemical and molecular testing for transcription factor E3 (TFE3) and/or EB (TFEB) translocation, was available for 65/122 patients. In this group, the most common histological subtypes were translocation type RCC (MiT-RCC) (36/64, 56.3%), papillary type (19/64, 29.7%) and clear cell type (4/64, 6.3%). One histological subtype was not reported. In the remaining 57 patients, translocation testing could not be performed, or TFE-cytogenetics and/or immunohistochemistry results were missing. In this group, the most common RCC histological subtypes were papillary type (21/47, 44.7%) and clear cell type (11/47, 23.4%). Ten histological subtypes were not reported. Estimated 5-year (5y) EFS and 5y OS of the total group was 70.5% (95% CI = 61.7%-80.6%) and 84.5% (95% CI = 77.5%-92.2%), respectively. Estimated 5y OS for localized, regionally advanced, and metastatic disease was 96.8%, 92.3%, and 45.6%, respectively. In conclusion, the registered pediatric patients with RCC showed a reasonable outcome. Survival was substantially lower for patients with metastatic disease. This descriptive study stresses the importance of full, prospective registration including TFE-testing.
KW - pediatric
KW - renal cell carcinoma
KW - survival
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=85100509309&partnerID=8YFLogxK
U2 - 10.1002/ijc.33476
DO - 10.1002/ijc.33476
M3 - Article
C2 - 33460450
SN - 0020-7136
VL - 148
SP - 2724
EP - 2735
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 11
ER -